Finland's Ambitious Pharmaceutical Vision
The pharmaceutical industry is gearing up to deliver a remarkable value proposition to the Finnish Government, with billions set to be invested by 2030. In recent years, the sector has shown robust growth, with over EUR 460 million funneled into the Finnish economy in 2023 alone. The investments split evenly between research and development (R&D) and production, highlighting the sector's commitment to both innovation and manufacturing capabilities.
Engagement with Government Officials
On a notable occasion, key representatives from the pharmaceutical sector presented their comprehensive value proposition to the Minister of Finance, aiming to align with the Finnish Government's growth strategies. The industry has expressed a strong willingness to elevate its investment in the pharmaceutical domain to EUR 1 billion by the end of the decade. However, achieving this ambitious goal necessitates improvements in the operational framework, especially to facilitate the introduction of new treatments.
Statements from Industry Leaders
Anne-Mari Virolainen, the Managing Director of Pharma Industry Finland (PIF), stated, "The global pharmaceutical industry tends to invest in regions known for their high standards of expertise and research excellence. In Finland, heightened focus on health and well-being has been recognized as crucial for social renewal, productivity, and economic growth." This underscores the industry's potential contribution to a flourishing economy.
Fostering Growth in Health and Well-Being
To further enhance the sector's trajectory, initiatives such as the 'Room for Growth' project are in the pipeline. This project aims to develop a specialized growth programme for the health and well-being sector, adding to the strategic research and development framework advocated by the Prime Minister’s Research and Innovation Council.
Export Trends and Contributions
In recent years, the health and pharmaceutical fields have emerged as leaders in investments and exports within Finland. Preliminary data indicated a significant surge in exports for 2024, especially in the chemical industry, with pharmaceutical products leading the charge with a 23.4% increase. This trend positions the pharmaceutical sector as vital in meeting Finland’s ambition to enhance R&D expenditure to 4% of its GDP.
Clinical Trials and Research Environment
Despite the positive investment climate, there remains a pressing concern regarding the declining number of clinical trials in Finland. Both the working group’s report and the RDI Growth Programme highlight the need for national coordination of research efforts to invigorate the R&D landscape.
Global Investment Insights
Globally, the pharmaceutical industry invests around EUR 300 billion annually in R&D, with European contributions estimated at about EUR 47 billion in 2023. Finland aims to ramp up its R&D spending from around EUR 230 million, aspiring to reach the EUR 1 billion threshold comparable to neighboring countries like Sweden and Denmark. This emphasis on R&D is expected to lay the groundwork for successful advancements from research to market-ready production.
Support Needed from the Government
For the pharmaceutical sector to realize its historic investment potential, government support is crucial. While various growth-enhancing measures are essential, it is equally necessary for decision-makers to avoid austerity measures that may impede this growth.
Contact Information:
Liisa Hurme, President and CEO, Orion Corporation
Email: liisa.hurme@orion.fi, Phone: +358 10 426 2874
Anne-Mari Virolainen, Managing Director, Pharma Industry Finland
Email: anne-mari.virolainen@pif.fi, Phone: +358 50 512 1941
Orion Corporation is a Finnish pharmaceutical enterprise that has sustained a legacy of fostering well-being for more than a century. Orion is engaged in the development, manufacturing, and marketing of both human and veterinary medicine, as well as active pharmaceutical ingredients. The company boasts an extensive portfolio that includes proprietary and generic medicines tailored to diverse health needs. Their primary areas of R&D focus are oncology and pain management, delivering treatments for conditions such as cancer and neurological disorders. In the fiscal year, Orion reported net sales of EUR 1,542 million and employed approximately 3,700 staff at year’s end. The company's A and B shares are traded on Nasdaq Helsinki.
Frequently Asked Questions
What is the main focus of the pharmaceutical investments in Finland?
The investments primarily aim at advancing R&D and enhancing production facilities within the pharmaceutical sector, ensuring growth and innovation.
Who presented the value proposition to the Finnish Government?
Key representatives from the pharmaceutical industry made the presentation to the Minister of Finance to discuss future investments and support needed.
Why is increasing R&D spending critical for Finland?
Increasing R&D spending is vital to strengthen Finland's position in the global market and foster advancements in healthcare and innovation.
How can the government support the pharmaceutical sector?
The government can support the sector by enhancing the operational environment, streamlining the approval processes for new treatments, and avoiding austerity measures that hamper growth.
What are the expectations for the future of the pharmaceutical industry in Finland?
The industry expects significant growth in investment and export potential, contributing to the economy and advancing health innovations.
